Trade

with

OncoGenex Pharmaceuticals Inc
(NASDAQ: OGXI)
AdChoices
2.17
-0.03
-1.36%
After Hours :
-
-
-

Open

2.20

Previous Close

2.20

Volume (Avg)

60.87k (143.31k)

Day's Range

2.15-2.23

52Wk Range

2.10-14.25

Market Cap.

45.87M

Dividend Rate ( Yield )

-

Beta

1.91

Shares Outstanding

21.14M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 29.88M

    • Net Income

    • -31.85M

    • Market Cap.

    • 45.87M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -92.19

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.91

    • Forward P/E

    • -

    • Price/Sales

    • 0.91

    • Price/Book Value

    • 1.73

    • Price/Cash flow

    • -1.41

      • EBITDA

      • -35.10M

      • Return on Capital %

      • -54.41

      • Return on Equity %

      • -81.83

      • Return on Assets %

      • -54.41

      • Book Value/Share

      • 1.25

      • Shares Outstanding

      • 21.14M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -1.61

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -22.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -92.19

            • 39.38

            • Net Profit Margin

            • -92.19

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -120.50

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -118.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 2.37

              • 2.92

              • Quick Ratio

              • 2.26

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.88

              • 2.21

              • Book Value/Share

              • 1.25

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.98

                • 238.10

                • P/E Ratio 5-Year High

                • -16.49

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.96

                • 124.82

                • Price/Sales Ratio

                • 0.90

                • 8.94

                • Price/Book Value

                • 1.71

                • 8.12

                • Price/Cash Flow Ratio

                • -1.41

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -81.83

                    (-42.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -54.41

                    (-24.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -81.83

                    (-37.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.59

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -35.33M
                  Operating Margin
                  -118.22
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.41
                  Ownership

                  Institutional Ownership

                  61.51%

                  Top 10 Institutions

                  52.63%

                  Mutual Fund Ownership

                  11.17%

                  Float

                  88.32%

                  5% / Insider Ownership

                  0.91%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Allianz Biotechnologie

                  •  

                    522,836

                  • 122.03

                  • 3.42

                  • Fidelity® Small Cap Stock Fund

                  •  

                    429,726

                  • 126.28

                  • 2.76

                  • Vanguard Total Stock Mkt Idx

                  •  

                    266,569

                  • 0.00

                  • 1.26

                  • TFS Market Neutral Fund

                  •  

                    181,229

                  • 43.32

                  • 1.16

                  • TIAA-CREF Small-Cap Equity

                  •  

                    162,740

                  • 0.00

                  • 0.77

                  • BlackRock Small Cap Growth Equity Port

                  •  

                    154,513

                  • 0.00

                  • 0.73

                  • Vanguard Extended Market Index Fund

                  •  

                    131,620

                  • 3.57

                  • 0.62

                  • Tekla Life Sciences Investors

                  •  

                    113,100

                  • 0.00

                  • 0.73

                  • Wasatch Ultra Growth Fund

                  •  

                    68,378

                  • -15.57

                  • 0.44

                  • iShares Micro-Cap

                  •  

                    54,915

                  • 0.00

                  • 0.21

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    683,312

                  • -9.65%

                  • 4.39

                  • Abingworth LLP

                  •  

                    603,740

                  • 0.00%

                  • 3.84

                  • Visium Asset Management LLC

                  •  

                    598,443

                  • 0.00%

                  • 3.84

                  • Allianz Global Investors

                  •  

                    522,836

                  • +101.25%

                  • 3.36

                  • Allianz Global Investors U.S. LLC

                  •  

                    522,836

                  • +122.03%

                  • 3.42

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Core

                  OncoGenex Pharmaceuticals Inc was incorporated in California in October 1991 and reorganized as a Delaware corporation in March 1995. The Company is a biopharmaceutical company engaged in the development and commercialization of ther...moreapies that address treatment resistance in cancer patients. It has three product candidates in pipeline: custirsen, apatorsen and OGX-225 of which custirsen is in Phase 3 clinical-stage and apatorsen is in Phase 2 clinical-stage. Custirsen is being evaluated in three phase 3 trials; two in patients with prostate cancer and one in patients with non-small cell lung cancer. A patorsen is designed to inhibit production of heat shock protein 27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast c...moreancers. OGX-225 is designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5, two proteins that affect the growth of cancer cells when overexpressed, observed in many human cancers, including prostate, breast, colorectal, non-small cell lung, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, and melanoma. In order to undertake clinical trials and to produce and market products for human use, the Company is subject to mandatory procedures and safety standards established by the FDA in the United States and by comparable agencies in other countries. The Company owns eight trademarks registered in the United States, namely ONCOGENEX, ORCA, Spruce, Rainier, ORCA and design, Pacific and design, Borealis-1 and design, and the helical totem design element that accompanies the clinical trial trademarked identifiers. In Canada, it has OncoGenex registered, and has corresponding Canadian trademark applications pending for the United States registrations. Additional trade-marks in use but still pending registration in both the United States and Canada trademark offices are Borealis-2, Cedar, and the OncoGenex script design.lessless

                  Key People

                  Mr. Scott Cormack

                  CEO/CEO, Subsidiary/Director/President/President, Subsidiary/Secretary/Treasurer

                  Dr. Jack Goldstein,PhD

                  Chairman of the Board/Director

                  Mr. John Bencich

                  CFO/Chief Accounting Officer/Vice President

                  Dr. Cindy Jacobs,PhD,M.D.

                  Chief Medical Officer/Executive VP

                  Mr. David V. Smith

                  Director

                  • OncoGenex Pharmaceuticals Inc

                  • 1522 - 217th Place SE

                  • Bothell, WA 98021

                  • USA.Map

                  • Phone: +1 425 686-1500

                  • Fax: -

                  • oncogenex.com

                  Incorporated

                  1991

                  Employees

                  41

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: